• Lexeo Therapeutics posted a Q1 net loss of USD 20.2 million, narrowing from USD 32.7 million a year earlier, while loss per share improved to USD 0.25 from USD 0.99.
• Operating loss narrowed to USD 22.33 million from USD 33.81 million, as total operating expenses fell to USD 22.33 million from USD 33.81 million.
• R&D spend dipped to USD 15.7 million from USD 17.2 million, while G&A expense dropped to USD 6.63 million from USD 16.63 million.
• Cash, cash equivalents and investments totaled USD 227.6 million at March 31, with runway expected into 2028.
• Protocol and statistical analysis plan for SUNRISE-FA 2 pivotal trial for LX2006 were submitted to FDA in Q1, with final feedback expected in Q2 and trial initiation targeted for Q2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexeo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605110700PRIMZONEFULLFEED9717170) on May 11, 2026, and is solely responsible for the information contained therein.